Novel oncolytic viruses: Riding high on the next wave?

Cytokine and Growth Factor Reviews

Volumn 21, Issue 2-3, 2010, Pages 177-183

  Stanford, Marianne M ^a   Bell, John C ^a   Vähä Koskela, Markus J V ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Oncolytic; Tumor; Virus

Indexed keywords

2 AMINOPURINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ONCOLYTIC ADENOVIRUS; ONCOLYTIC HERPES VIRUS; ONCOLYTIC MYXOMAVIRUS; ONCOLYTIC RACCOONPOX VIRUS; ONCOLYTIC SEMLIKI FOREST ALPHAVIRUS; ONCOLYTIC VACCINIA VIRUS; ONCOLYTIC VESICULAR STOMATITIS VIRUS; ONCOLYTIC VIRUS; ONYX 015; RAPAMYCIN; UNCLASSIFIED DRUG;

BRAIN TUMOR; CANCER CELL DESTRUCTION; CANCER RESISTANCE; CELL KILLING; CLINICAL TRIAL; DNA MODIFICATION; GLIOMA; GROWTH INHIBITION; HUMAN; HYPOXIA; IMMUNOGENICITY; IMMUNOMODULATION; INTERFERON INDUCTION; LUNG METASTASIS; MYXOMA VIRUS; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; RECTUM CARCINOMA; REVIEW; SEMLIKI FOREST ALPHAVIRUS; SOLID TUMOR; TUMOR; UNSPECIFIED SIDE EFFECT; VESICULAR STOMATITIS VIRUS; VIRUS REPLICATION; VIRUS VIRULENCE; ANIMAL; CLINICAL TRIAL (TOPIC); GENE THERAPY; GENE VECTOR; NEOPLASMS; PATHOLOGY; PROCEDURES; VIRAL TROPISM;

ANIMALS; CLINICAL TRIALS AS TOPIC; GENE THERAPY; GENETIC VECTORS; HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; VIRAL TROPISM; VIRUS REPLICATION; GENETIC THERAPY;

EID: 77953534287     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2010.02.012     Document Type: Review

References (73)

1. Kelly E., Russell S.J. History of oncolytic viruses: genesis to genetic engineering. Mol Ther 2007, 15:651-659.
2. Martuza R.L., Malick A., Markert J.M., Ruffner K.L., Coen D.M. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991, 252:854-856.
3. Kasuya H., Takeda S., Shimoyama S., Shikano T., Nomura N., Kanazumi N., et al. Oncolytic virus therapy-foreword. Curr Cancer Drug Targets 2007, 7:123-125.
4. Vähä-Koskela M.J., Heikkilä J.E., Hinkkanen A.E. Oncolytic viruses in cancer therapy. Cancer Lett 2007, 254:178-216.
5. Hardcastle J., Kurozumi K., Chiocca E.A., Kaur B. Oncolytic viruses driven by tumor-specific promoters. Curr Cancer Drug Targets 2007, 7:181-189.
6. Sinkovics J.G., Horvath J.C. Newcastle disease virus (NDV): brief history of its oncolytic strains. J Clin Virol 2000, 16:1-15.
7. Liu T.C., Galanis E., Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 2007, 4:101-117.
8. Kanerva A., Hemminki A. Adenoviruses for treatment of cancer. Ann Med 2005, 37:33-43.
9. Ylösmäki E., Hakkarainen T., Hemminki A., Visakorpi T., Andino R., Saksela K. Generation of a conditionally replicating adenovirus-based on targeted destruction of E1A mRNA by a cell type-specific MicroRNA. J Virol 2008, 82:11009-11015.
10. Edge R.E. A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication. Mol Ther 2008.
11. Yu Y.A., Shabahang S., Timiryasova T.M., Zhang Q., Beltz R., Gentschev I., et al. Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat Biotechnol 2004, 22:313-320.
12. Goel A., Carlson S.K., Classic K.L., Greiner S., Naik S., Power A.T., et al. Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium-iodide symporter gene. Blood 2007, 110:2342-2350.
13. Guo W., Zhu H., Zhang L., Davis J., Teraishi F., Roth J.A., et al. Combination effect of oncolytic adenovirotherapy and TRAIL gene therapy in syngeneic murine breast cancer models. Cancer Gene Ther 2006, 13:82-90.
14. Sova P., Ren X.W., Ni S., Bernt K.M., Mi J., Kiviat N., et al. A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. Mol Ther 2004, 9:496-509.
15. Crompton A.M., Kirn D.H. From ONYX-015 to armed vaccinia viruses: the education and evolution of oncolytic virus development. Curr Cancer Drug Targets 2007, 7:133-139.
16. Malhotra S., Kim T., Zager J., Bennett J., Ebright M., D'Angelica M., et al. Use of an oncolytic virus secreting GM-CSF as combined oncolytic and immunotherapy for treatment of colorectal and hepatic adenocarcinomas. Surgery 2007, 141:520-529.
17. Simpson G.R., Han Z., Liu B., Wang Y., Campbell G., Coffin R.S. Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control. Cancer Res 2006, 66:4835-4842.
18. Kasuya H., Takeda S., Nomoto S., Nakao A. The potential of oncolytic virus therapy for pancreatic cancer. Cancer Gene Ther 2005, 12:725-736.
19. Kim J.H., Oh J.Y., Park B.H., Lee D.E., Kim J.S., Park H.E., et al. Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. Mol Ther 2006, 14:361-370.
20. Cattaneo R., Miest T., Shashkova E.V., Barry M.A. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 2008, 6:529-540.
21. Lichty B.D., Power A.T., Stojdl D.F., Bell J.C. Vesicular stomatitis virus: re-inventing the bullet. Trends Mol Med 2004, 10:210-216.
22. Stojdl D.F., Lichty B., Knowles S., Marius R., Atkins H., Sonenberg N., et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000, 6:821-825.
23. Balachandran S., Porosnicu M., Barber G.N. Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis. J Virol 2001, 75:3474-3479.
24. Oliere S., Arguello M., Mesplede T., Tumilasci V., Nakhaei P., Stojdl D., et al. Vesicular stomatitis virus oncolysis of T lymphocytes requires cell cycle entry and translation initiation. J Virol 2008, 82:5735-5749.
25. Krishnamoorthy J., Mounir Z., Raven J.F., Koromilas A.E. The eIF2alpha kinases inhibit vesicular stomatitis virus replication independently of eIF2alpha phosphorylation. Cell Cycle 2008, 7:2346-2351.
26. Breitbach C.J., Paterson J.M., Lemay C.G., Falls T.J., McGuire A., Parato K.A., et al. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther 2007, 15:1686-1693.
27. Altomonte J., Wu L., Chen L., Meseck M., Ebert O., Garcia-Sastre A., et al. Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo. Mol Ther 2008, 16:146-153.
28. Kottke T., Diaz R.M., Kaluza K., Pulido J., Galivo F., Wongthida P., et al. Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer. Mol Ther 2008, 16:1910-1918.
29. Newman W., Southam C.M. Virus treatment in advanced cancer; a pathological study of fifty-seven cases. Cancer 1954, 7:106-118.
30. Smyth J.W., Fleeton M.N., Sheahan B.J., Atkins G.J. Treatment of rapidly growing K-BALB and CT26 mouse tumors using Semliki Forest virus and its derived vector. Gene Ther 2005, 12:147-159.
31. Vähä-Koskela M.J., Kallio J.P., Jansson L.C., Heikkilä J.E., Zakhartchenko V.A., Kallajoki M.A., et al. Oncolytic capacity of attenuated replicative Semliki Forest virus in human melanoma xenografts in severe combined immunodeficient mice. Cancer Res 2006, 66:7185-7194.
32. Määttä A.M., Liimatainen T., Wahlfors T., Wirth T., Vähä-Koskela M., Jansson L., et al. Evaluation of cancer virotherapy with attenuated replicative Semliki Forest virus in different rodent tumor models. Int J Cancer 2007, 121:863-870.
33. Atkins G.J., Fleeton M.N., Sheahan B.J. Therapeutic and prophylactic applications of alphavirus vectors. Expert Rev Mol Med 2008, 10:e33.
34. Tseng J.C., Levin B., Hurtado A., Yee H., Perez, dC I., et al. Systemic tumor targeting and killing by Sindbis viral vectors. Nat Biotechnol 2004, 22:70-77.
35. Liu T.C., Hwang T., Park B.H., Bell J., Kirn D.H. The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther 2008, 16:1637-1642.
36. Park B.H., Hwang T., Liu T.C., Sze D.Y., Kim J.S., Kwon H.C., et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 2008, 9:533-542.
37. Kretzschmar M., Wallinga J., Teunis P., Xing S., Mikolajczyk R. Frequency of adverse events after vaccination with different vaccinia strains. PLoS Med 2006, 3:e272.
38. Stanford M.M., McFadden G. Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer. Expert Opin Biol Ther 2007, 7:1415-1425.
39. Wang G., Barrett J.W., Stanford M., Werden S.J., Johnston J.B., Gao X., et al. Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc Natl Acad Sci U S A 2006, 103:4640-4645.
40. Wang F., Gao X., Barrett J.W., Shao Q., Bartee E., Mohamed M.R., et al. RIG-I mediates the co-induction of tumor necrosis factor and type I interferon elicited by myxoma virus in primary human macrophages. PLoS Pathog 2008, 4:e1000099.
41. Wang F., Barrett J.W., Shao Q., Gao X., Dekaban G.A., McFadden G. Myxoma virus selectively disrupts type I interferon signaling in primary human fibroblasts by blocking the activation of the Janus kinase Tyk2. Virology 2009, 387:136-146.
42. Lun X., Yang W., Alain T., Shi Z.Q., Muzik H., Barrett J.W., et al. Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. Cancer Res 2005, 65:9982-9990.
43. Stanford M.M., Shaban M., Barrett J.W., Werden S.J., Gilbert P.A., Bondy-Denomy J., et al. Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo. Mol Ther 2008, 16:52-59.
44. Stanford M.M., Barrett J.W., Nazarian S.H., Werden S., McFadden G. Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells. J Virol 2007, 81:1251-1260.
45. Lun X.Q., Jang J.H., Tang N., Deng H., Head R., Bell J.C., et al. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide. Clin Cancer Res 2009, 15:2777-2788.
46. Thomas E.K., Palmer E.L., Obijeski J.F., Nakano J.H. Further characterization of Raccoonpox virus. Arch Virol 1975, 49:217-227.
47. Rocke T.E., Dein F.J., Fuchsberger M., Fox B.C., Stinchcomb D.T., Osorio J.E. Limited infection upon human exposure to a recombinant raccoon pox vaccine vector. Vaccine 2004, 22:2757-2760.
48. Huszthy P.C., Goplen D., Thorsen F., Immervoll H., Wang J., Gutermann A., et al. Oncolytic herpes simplex virus type-1 therapy in a highly infiltrative animal model of human glioblastoma. Clin Cancer Res 2008, 14:1571-1580.
49. Thomas M.A., Broughton R.S., Goodrum F.D., Ornelles D.A. E4orf1 limits the oncolytic potential of the E1B-55K deletion mutant adenovirus. J Virol 2009, 83:2406-2416.
50. Coffey M.C., Strong J.E., Forsyth P.A., Lee P.W. Reovirus therapy of tumors with activated Ras pathway. Science 1998, 282:1332-1334.
51. Farassati F., Yang A.D., Lee P.W. Oncogenes in Ras signalling pathway dictate host cell permissiveness to herpes simplex virus 1. Nat Cell Biol 2001, 3:745-750.
52. Barry G., Breakwell L., Fragkoudis R., Attarzadeh-Yazdi G., Rodriguez-Andres J., Kohl A., et al. PKR acts early in infection to suppress Semliki Forest virus production and strongly enhances the type I interferon response. J Gen Virol 2009, 90:1382-1391.
53. Ryman K.D., White L.J., Johnston R.E., Klimstra W.B. Effects of PKR/RNase L-dependent and alternative antiviral pathways on alphavirus replication and pathogenesis. Viral Immunol 2002, 15:53-76.
54. Tesfay M.Z., Yin J., Gardner C.L., Khoretonenko M.V., Korneeva N.L., Rhoads R.E., et al. Alpha/beta interferon inhibits cap-dependent translation of viral but not cellular mRNA by a PKR-independent mechanism. J Virol 2008, 82:2620-2630.
55. Ketola A., Hinkkanen A., Yongabi F., Furu P., Määttä A.M., Liimatainen T., et al. Oncolytic Semliki Forest virus vector as a novel candidate against unresectable osteosarcoma. Cancer Res 2008, 68:8342-8350.
56. Carey B.L., Ahmed M., Puckett S., Lyles D.S. Early steps of the virus replication cycle are inhibited in prostate cancer cells resistant to oncolytic vesicular stomatitis virus. J Virol 2008, 82:12104-12115.
57. Wollmann G., Robek M.D., van den Pol A.N. Variable deficiencies in the interferon response enhance susceptibility to vesicular stomatitis virus oncolytic actions in glioblastoma cells but not in normal human glial cells. J Virol 2007, 81:1479-1491.
58. Saloura V., Wang L.C., Fridlender Z.G., Sun J., Cheng G., Kapoor V., et al. Evaluation of an attenuated vesicular stomatitis virus (VSV) vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon-responsiveness defines potential efficacy. Hum Gene Ther 2009.
59. Pfeffer L.M., Wang C., Constantinescu S.N., Croze E., Blatt L.M., Albino A.P., et al. Human renal cancers resistant to IFN's antiproliferative action exhibit sensitivity to IFN's gene-inducing and antiviral actions. J Urol 1996, 156:1867-1871.
60. Hwang I.I., Watson I.R., Der S.D., Ohh M. Loss of VHL confers hypoxia-inducible factor (HIF)-dependent resistance to vesicular stomatitis virus: role of HIF in antiviral response. J Virol 2006, 80:10712-10723.
61. Pipiya T., Sauthoff H., Huang Y.Q., Chang B., Cheng J., Heitner S., et al. Hypoxia reduces adenoviral replication in cancer cells by downregulation of viral protein expression. Gene Ther 2005, 12:911-917.
62. Stanford M.M., Breitbach C.J., Bell J.C., McFadden G. Innate immunity, tumor microenvironment and oncolytic virus therapy: friends or foes?. Curr Opin Mol Ther 2008, 10:32-37.
63. Prestwich R.J., Errington F., Diaz R.M., Pandha H., Harrington K.J., Melcher A.A., et al. The case of oncolytic viruses vs the immune system: waiting on the judgment of solomon. Hum Gene Ther 2009.
64. Bauzon M., Hermiston T.W. Exploiting diversity: genetic approaches to creating highly potent and efficacious oncolytic viruses. Curr Opin Mol Ther 2008, 10:350-355.
65. Nguyen T.L., Abdelbary H., Arguello M., Breitbach C., Leveille S., Diallo J.S., et al. Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc Natl Acad Sci U S A 2008, 105:14981-14986.
66. Kolodkin-Gal D., Edden Y., Hartshtark Z., Ilan L., Khalaileh A., Pikarsky A.J., et al. Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect. Gene Ther 2009, 16:905-915.
67. Haralambieva I., Iankov I., Hasegawa K., Harvey M., Russell S.J., Peng K.W. Engineering oncolytic measles virus to circumvent the intracellular innate immune response. Mol Ther 2007, 15:588-597.
68. Zamarin D., Martinez-Sobrido L., Kelly K., Mansour M., Sheng G., Vigil A., et al. Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses. Mol Ther 2009, 17:697-706.
69. Gardner C.L., Yin J., Burke C.W., Klimstra W.B., Ryman K.D. Type I interferon induction is correlated with attenuation of a South American eastern equine encephalitis virus strain in mice. Virology 2009, 390:338-347.
70. Stojdl D.F., Lichty B.D., tenOever B.R., Paterson J.M., Power A.T., Knowles S., et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003, 4:263-275.
71. Edge R.E., Falls T.J., Brown C.W., Lichty B.D., Atkins H., Bell J.C. A let-7 MicroRNA-sensitive vesicular stomatitis virus demonstrates tumor-specific replication. Mol Ther 2008, 16:1437-1443.
72. Heikkilä JE, Vähä-Koskela MJ, Ruotsalainen JJ, Martikainen MW, Stanford MM, McCart JA, Bell JC, Hinkkanen AE. Intravenously administered alphavirus vector VA7 eradicates orthotopic human glioma xenografts in nude mice. PLoS One. 2010 Jan 6;5(1):e8603.
73. Evgin L, Vähä-Koskela M, Rintoul J, Falls T, Le Boeuf F, Barrett JW, Bell JC, Stanford MM. Potent Oncolytic Activity of Raccoonpox Virus in the Absence of Natural Pathogenicity. Mol Ther. 2010 Feb 16. [Epub ahead of print].